Cor Vasa 2023, 65(4):705-709 | DOI: 10.33678/cor.2023.031

(Loeffler endocarditis (pancarditis) as a rare cause of heart failure)

Patrik Šulca, Jiří Pudicha, Martin Plevab, Jan Václavíka
a Interní a kardiologická klinika, Fakultní nemocnice Ostrava, Ostrava
b Kardiologické oddělení, Nemocnice AGEL Třinec-Podlesí, Třinec

We present a case of a 32-year-old patient suffering from Löffler (Loeffler) endocarditis, respectively pancarditis, as a rare cause of heart failure. The patient was diagnosed with eosinophillic granulomatosis with polyangiitis as a secondary hypereosinophillic syndrome. Main diagnostic tool for cardiac damage was cardiac magnetic resonance which showed signs of pancarditis, decreased left ventricular ejection fraction, and apical thrombus. The patient needed treatment of acute heart failure, immunosuppressive and other therapy for multi-organ damage caused by the primary disease. We decided not to perform a cardiac biopsy due to high periprocedural risk of systemic embolism. Initial and long-term therapy was effective, leading to remission, reverse remodeling of the left ventricle and disappearance of the thrombus.

Keywords: Eosinophillic granulomatosis with polyangiitis, Heart failure, Hypereosinophilic syndrome, Loeffler endocarditis

Received: February 7, 2023; Revised: April 4, 2023; Accepted: April 14, 2023; Published: September 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šulc P, Pudich J, Pleva M, Václavík J. (Loeffler endocarditis (pancarditis) as a rare cause of heart failure). Cor Vasa. 2023;65(4):705-709. doi: 10.33678/cor.2023.031.
Download citation

References

  1. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol 2019;94:1149-1167. Go to original source... Go to PubMed...
  2. Mubarik A, Iqbal AM. Loeffler Endocarditis. [Updated 2022 Aug 22]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan. Dostupné na: https://www.ncbi.nlm.nih.gov/books/NBK534850/. Navštíveno: 13. 8. 2023.
  3. Grayson PC, Ponte C, Suppiah R, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 2022;81:309-314. Go to original source... Go to PubMed...
  4. Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: an overview. Front Immunol 2014;5:549. Go to original source... Go to PubMed...
  5. Kanuru S, Sapra A. Eosinophilia 2022 Sep 26. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 32809764. Dostupný na: https://www.ncbi.nlm.nih.gov/books/NBK560929/ Navštíveno: 13. 8. 2023.
  6. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007;27:457-475. Go to original source... Go to PubMed...
  7. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.; DAPA--CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.





Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.